All In Biotech

Drug Trial Radar · NCT00189514

A Study to Examine the Long Term Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects

Extension Study of Protocol 137OB-201 to Examine the Long Term Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects

Last checked: Nov 20, 2026Latest source record: Jun 11, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 210 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

210

Actual

Start

Sep 2005

Primary completion

Jun 2007

Study completion Jun 2007

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Sep 19, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a long term extension to study 137OB-201 which is designed to examine the effect of pramlintide on body weight and its safety and tolerability in obese subjects.

Conditions

  • Obesity

Interventions

  • pramlintide acetateDrug

    Subcutaneous injection, twice a day or three times a day, at doses of 120mcg, 240mcg, or 360mcg

  • placeboDrug

    subcutaneous injection, three times a day, volumes equivalent to 120mcg, 240mcg, or 360mcg of pramlintide acetate

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Examine the long-term effect of subcutaneously (SC) injected pramlintide on body weight in obese subjects.Time frame: open ended
  2. Examine the long-term safety and tolerability of SC injected pramlintide in obese subjects.Time frame: open ended

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Chula Vista, California

  • Research Site

    San Diego, California

  • Research Site

    Walnut Creek, California

  • Research Site

    Miami, Florida

  • Research Site

    Augusta, Georgia

  • Research Site

    Chicago, Illinois

  • Research Site

    Indianapolis, Indiana

  • Research Site

    Overland Park, Kansas

  • Research Site

    Baton Rouge, Louisiana

  • Research Site

    Detroit, Michigan

  • Research Site

    Edina, Minnesota

  • Research Site

    St Louis, Missouri

  • Research Site

    Butte, Montana

  • Research Site

    New York, New York

  • Research Site

    Cincinnati, Ohio

  • Research Site

    Portland, Oregon

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    Austin, Texas

  • Research Site

    San Antonio, Texas

  • Research Site

    Salt Lake City, Utah

  • Research Site

    Olympia, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.